Law360, New York (January 29, 2018, 3:27 PM EST) — Paul Hastings LLP convinced the U.S. Patent Trial and Appeal Board to invalidate a major patent covering AbbVie’s $16 billion biologic Humira and uphold four patents covering an Acorda Therapeutics Inc. multiple sclerosis drug, landing the firm a …
